News & Updates

In the management of statin-treated patients with elevated cholesterol levels, the antisense oligonucleotide targeting angiopoietin-like protein 3 (ANGPTL3) vupanorsen reduces levels of nonhigh-density lipoprotein cholesterol (non-HDL-C) and other lipid parameters, according to the results of TRANSLATE-TIMI 70.

Variance in visual field (VD) damage is substantially driven by five patient-reported symptoms, according to a cross-sectional study.

The combination of lenalidomide plus ixazomib in the maintenance treatment of patients with post-transplant myeloma leads to better progression-free survival (PFS) compared with lenalidomide alone in historical controls, according to a study.

Vupanorsen significantly reduces non–high-density lipoprotein cholesterol (non-HDL-C) levels in adults with hyperlipidaemia already taking statins, according to the TRANSLATE-TIMI 70* trial presented at ACC 2022.

Treatment with the combination of tamsulosin plus mirabegron following 125I-brachytherapy for prostate cancer falls short of improving voiding volume compared with tamsulosin monotherapy, although the combination helps with urination frequency and overactive bladder symptoms, according to a study.

First-line treatment with nivolumab – be it in combination with chemotherapy (CT) or with ipilimumab – provided overall survival (OS) benefit and durable responses than CT alone in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to findings from the phase III CheckMate 648 trial.